TY - JOUR
T1 - Impact of 2-Deoxy-2[F-18]Fluoro-D-Glucose positron emission tomography on the management of patients with advanced melanoma
AU - Harris, Marion T.
AU - Berlangieri, Salvatore U.
AU - Cebon, Jonathan S.
AU - Davis, Ian D.
AU - Scott, Andrew M.
PY - 2006/7/1
Y1 - 2006/7/1
N2 - Purpose: Accurate staging of patients with melanoma is vital to guide appropriate treatment. 2-Deoxy-2-[F-18]fluoro-D-glucose (FDG)-positron emission tomography (PET) has been reported to be a sensitive and specific technique for the staging of advanced melanoma, however, few studies provide information regarding its impact on patient management. Procedures: We retrospectively reviewed the FDG-PET scan results of 92 patients with melanoma who had 126 scans performed over a six-year period. These patients were seen at the specialist melanoma clinic at our Institution, and 84 patients (92%) had stage III or IV disease. FDG-PET scan results were correlated with computed tomography (CT) scans and other imaging when available, and with clinical follow-up of a minimum of three to six months. The impact of FDG-PET scans on patient management was also assessed. Results: On a lesion-by-lesion analysis, FDG-PET had a sensitivity of 92%, a specificity of 88%, and an accuracy of 91%. FDG-PET correctly affected the clinical decision-making process in 40 of 126 patient studies (32%), particularly assisting in the selection of patients for surgery. Conclusion: FDG-PET has an important role in guiding the management of patients with advanced melanoma, particularly when surgery is contemplated.
AB - Purpose: Accurate staging of patients with melanoma is vital to guide appropriate treatment. 2-Deoxy-2-[F-18]fluoro-D-glucose (FDG)-positron emission tomography (PET) has been reported to be a sensitive and specific technique for the staging of advanced melanoma, however, few studies provide information regarding its impact on patient management. Procedures: We retrospectively reviewed the FDG-PET scan results of 92 patients with melanoma who had 126 scans performed over a six-year period. These patients were seen at the specialist melanoma clinic at our Institution, and 84 patients (92%) had stage III or IV disease. FDG-PET scan results were correlated with computed tomography (CT) scans and other imaging when available, and with clinical follow-up of a minimum of three to six months. The impact of FDG-PET scans on patient management was also assessed. Results: On a lesion-by-lesion analysis, FDG-PET had a sensitivity of 92%, a specificity of 88%, and an accuracy of 91%. FDG-PET correctly affected the clinical decision-making process in 40 of 126 patient studies (32%), particularly assisting in the selection of patients for surgery. Conclusion: FDG-PET has an important role in guiding the management of patients with advanced melanoma, particularly when surgery is contemplated.
KW - Clinical management
KW - Melanoma
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=33646788729&partnerID=8YFLogxK
U2 - 10.1007/s11307-005-0002-7
DO - 10.1007/s11307-005-0002-7
M3 - Review Article
C2 - 16041590
AN - SCOPUS:33646788729
VL - 7
SP - 304
EP - 308
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
SN - 1536-1632
IS - 4
ER -
